Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson bought 5,000 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The stock was acquired at an average price of $3.79 per share, for a total transaction of $18,950.00. Following the completion of the purchase, the director now directly owns 3,077,550 shares in the company, valued at $11,663,914.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

James George Robinson also recently made the following trade(s):

  • On Thursday, August 3rd, James George Robinson bought 10,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average price of $3.73 per share, for a total transaction of $37,300.00.
  • On Tuesday, August 1st, James George Robinson bought 15,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average price of $3.72 per share, for a total transaction of $55,800.00.
  • On Thursday, July 6th, James George Robinson bought 3,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average price of $3.92 per share, for a total transaction of $11,760.00.
  • On Wednesday, July 5th, James George Robinson bought 5,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average price of $3.97 per share, for a total transaction of $19,850.00.
  • On Friday, July 7th, James George Robinson bought 11,500 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average price of $4.00 per share, for a total transaction of $46,000.00.
  • On Wednesday, June 28th, James George Robinson bought 8,500 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average price of $4.09 per share, for a total transaction of $34,765.00.
  • On Monday, June 26th, James George Robinson bought 15,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average price of $3.80 per share, for a total transaction of $57,000.00.
  • On Tuesday, June 20th, James George Robinson bought 5,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average price of $3.76 per share, for a total transaction of $18,800.00.
  • On Monday, June 19th, James George Robinson bought 5,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average price of $3.79 per share, for a total transaction of $18,950.00.
  • On Wednesday, June 21st, James George Robinson bought 15,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average price of $3.77 per share, for a total transaction of $56,550.00.

Shares of Nymox Pharmaceutical Corporation (NASDAQ NYMX) traded down 1.35% during trading on Friday, reaching $3.66. The company’s stock had a trading volume of 58,076 shares. The company has a 50 day moving average of $3.96 and a 200 day moving average of $3.79. The company’s market cap is $184.64 million. Nymox Pharmaceutical Corporation has a 12-month low of $1.62 and a 12-month high of $5.79.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/08/04/nymox-pharmaceutical-corporation-nymx-director-james-george-robinson-purchases-5000-shares.html.

Institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers acquired a new position in shares of Nymox Pharmaceutical Corporation during the second quarter valued at approximately $134,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Nymox Pharmaceutical Corporation during the second quarter valued at approximately $222,000. Bank of New York Mellon Corp acquired a new position in shares of Nymox Pharmaceutical Corporation during the second quarter valued at approximately $323,000. Finally, Wedbush Securities Inc. increased its position in shares of Nymox Pharmaceutical Corporation by 30.6% in the second quarter. Wedbush Securities Inc. now owns 234,692 shares of the biopharmaceutical company’s stock valued at $1,033,000 after buying an additional 55,000 shares during the last quarter. Institutional investors and hedge funds own 1.78% of the company’s stock.

Separately, ValuEngine lowered Nymox Pharmaceutical Corporation from a “hold” rating to a “sell” rating in a research note on Monday, July 24th.

Nymox Pharmaceutical Corporation Company Profile

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

Insider Buying and Selling by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

Receive News & Ratings for Nymox Pharmaceutical Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Corporation and related companies with MarketBeat.com's FREE daily email newsletter.